Introduction
============

Neonates and infants in the ICU are at high risk of severe infections and sepsis. Often it is not easy to diagnose sepsis based only on clinical findings; reliable biomarkers are needed to prove the diagnosis.

Objective
=========

To study the value of procalcitonin (PCT) as a marker, verifying the diagnosis, which enables the start of de-escalating ABT in patients with clinical signs of sepsis.

Methods
=======

Three hundred and seventy-four patients on artificial lung ventilation from two pediatric ICUs of two Russian hospitals were enrolled. Blood samples for PCT testing (PCT LIA; BRAHMS AG, Germany) were taken under suspicion of sepsis or exacerbation of bacterial infection. In the first stage (January--December 2005), 50 neonates (age 6 (4--12) days) with various perinatal pathologies were studied (Group A), and routine ABT was prescribed, with blood samples taken and stored for further PCT assessment. In the second stage (January--November 2006), 324 infants (age 6 (1.5--9.4) months) after cardiac surgery were enrolled (Group B), and ABT was adjusted based on PCT-testing results. PCT \> 2 ng/ml indicative of systemic bacterial inflammation in addition to clinical signs of sepsis was an indication for ABT with carbapenems. Data are shown as the median and interquartile range.

Results
=======

Group A
-------

Sepsis was diagnosed in 16/50 (32%) patients. PCT \> 2 ng/ml was observed in 23/50 (46%) cases, including 15/16 (94%) patients with clinically diagnosed sepsis. In patients with PCT \> 2 ng/ml the mortality rate was 7.7% if carbapenems (meropenem or imipenem/cilastatin) were administered (*n*= 13), compared with 20% with different ABT (*n*= 10) -- although in patients with PCT \< 2 ng/ml (*n*= 27), ABT with carbapenems (*n*= 12) resulted in paradoxically higher mortality compared with other ABT schemes (*n*= 15): 17% vs 6.6%.

Group B
-------

Sepsis was defined in 24/324 (7.4%) patients. PCT \> 2 ng/ml was in 53/324 (16%) cases, including all patients with clinically diagnosed sepsis. Early ABT with meropenem, combined with vancomycin or linezolid, allowed one to decrease sepsis-related mortality in these patients to 29%, which used to be as high as 74% before the introduction of this algorithm (*P*= 0.0028).

Conclusion
==========

Early verification of sepsis using PCT combined with carbapenems-based ABT enables decreasing sepsis-related mortality in critically ill infants and newborns staying in the ICU.
